Vyriad is a clinical-stage company that is committed to improving lives through innovative medicines that inspire hope. They specialize in developing proprietary oncolytic virus therapies to treat cancers with significant unmet needs. The ground-breaking oncolytic viral technologies of Vyriad are the result of extensive research conducted by dedicated researchers and clinicians at renowned institutions such as Mayo Clinic, Imanis Life Sciences, and the University of Miami.

The company holds exclusive licenses to technologies discovered and validated in the Department of Molecular Medicine founded by Vyriad CEO Dr. Stephen Russell at Mayo Clinic. This, along with their comprehensive oncolytic virotherapy program, sets Vyriad apart in the field.

Additionally, Dr. Glen Barber, a pioneering researcher in innate immunity and virotherapies, has made significant contributions to their advancements in the Department of Cell Biology at the University of Miami Miller School of Medicine. Headquartered in Rochester, Minnesota, Vyriad is part of Medical Alley, a prestigious network that provides access to expertise and resources, enabling them to advance new technologies and ultimately improve the lives of patients.

Through their dedication and cutting-edge research, Vyriad is paving the way for transformative treatments in the fight against cancer